Join our 20.000 subscribers and receive the monthly newsletter for free!

RELATED ARTICLES
argenx signs billion-dollar deal with Janssen

Another Belgian biotech on the up and up: argenx just closed a billion-dollar deal with Janssen Pharmaceutica for their antibody cusatuzumab. Unde…


All in on cancer immunotherapy

Founded in 2011, iTeos Therapeutics began its activities at the end of 2012. Active in the field of cancer immunotherapy, the company develops inn…


arGEN-x receives €1.5 million for enhancement of therapeutic antibodies

In early May 2015, arGEN-X N.V. (ARGX) received a €1.5 million grant from the Flemish IWT (the government agency for Innovation by Science and Tec…

POPULAR TAGS

argenx receives first preclinical milestone payment in AbbVie collaboration

Written by LVS on in the category news with the tags , , .


argenx announced today the achievement of the first of two preclinical milestones on its way to the investigational new drug (IND) filing of ARGX-115, triggering a $ 10 million payment from AbbVie.

In April 2016, argenx entered into a collaboration agreement with AbbVie to develop and commercialize ARGX-115. Under the terms of the collaboration agreement, argenx is responsible for conducting and funding all ARGX-115 research and development activities up to completion of IND-enabling studies.
argenx has granted AbbVie an exclusive option, for a period following completion of IND-enabling studies, to obtain a worldwide, exclusive license to the ARGX-115 program to develop and commercialize products. argenx is eligible to receive two near-term preclinical milestones of $ 10 million each. The first milestone was achieved today.

Read more on argenx

ARGX-115 employs argenx's SIMPLE Antibody(TM) technology and works by stimulating a patient's immune system after a tumor has suppressed the immune system by co-opting immunosuppressive cells such as activated regulatory T-cells (Tregs). While the normal function of Tregs is to suppress portions of the immune system to prevent a self-directed immune response through the release of active transforming growth factor beta (TGF-beta), Tregs can also prevent the immune system from recognizing and suppressing pathogenic cells including cancer cells. By binding to glycoprotein A repetitions predominant (GARP), which plays a key role in the regulation of production and release of active TGF-beta, ARGX-115 works to limit the immunosuppressive activity of Tregs and thereby stimulate the immune system to attack cancer cells. We believe this specific inhibition of TGF-beta release by Tregs is potentially superior as a therapy to systemic inhibition of TGF-beta activity or the depletion of Tregs with a potentially improved safety profile.

ARGX-115 was discovered under argenx's Innovative Access Program with the de Duve Institute / Université Catholique de Louvain / WELBIO.

Read more about: , , .

RELATED ARTICLES
argenx signs billion-dollar deal with Janssen

Another Belgian biotech on the up and up: argenx just closed a billion-dollar deal with Janssen Pharmaceutica for their antibody cusatuzumab. Unde…


All in on cancer immunotherapy

Founded in 2011, iTeos Therapeutics began its activities at the end of 2012. Active in the field of cancer immunotherapy, the company develops inn…


arGEN-x receives €1.5 million for enhancement of therapeutic antibodies

In early May 2015, arGEN-X N.V. (ARGX) received a €1.5 million grant from the Flemish IWT (the government agency for Innovation by Science and Tec…

POPULAR TAGS

Sign up to our Mailing List to receive updates
of our latest News, Events & Magazines

Itera Life Science V-Bio Ventures UGent Flanders.bio Biowin KU Leuven XpandInnovation Janssen Turnstone GSK

ABOUT BIOVOX - Sharing Life Sciences Innovations

BioVox showcases interesting life sciences breakthroughs for and from Belgian innovators. Through our partnership with BioCentury we share relevant worldwide innovations and business updates while our local journalists focus on regional highlights. 

Interested to get involved? Get in touch! We are looking for content, writers and partners! Blogs are available for research institutes, companies and freelance experts.

You want to reach out to the biotechnology and life sciences community, targetting selected audiences? Discover our sponsor and publication opportunities as well as tailored packages!

Contact BioVox via news@biovox.be or by completing the contact form.